Ebos Group (ASX:EBO) EBIT: A$398 Mil (TTM As of Dec. 2025)


ASX:EBO Ebos Group Ltd ASX:EBO
77 GF Score
Price A$16.76
GF Value A$31.49
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Ebos Group EBIT?

Ebos Group ASX:EBO +0.30% 77 EBIT is A$398 Mil as of Dec. 2025. GuruFocus rates ASX:EBO with a GF Score™ of 77/100 and a GF Value™ of A$31.49 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Ebos Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was A$211 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was A$398 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ebos Group's annualized ROC % for the quarter that ended in Dec. 2025 was 6.32%. Ebos Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 30.96%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ebos Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 8.12%.

Ebos Group  (ASX:EBO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ebos Group's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=386.838 * ( 1 - 22.23% )/( (4644.006 + 4871.749)/ 2 )
=300.8439126/4757.8775
=6.32 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7264.738 - 2436.823 - ( 183.909 - max(0, 2610.065 - 3080.331+183.909))
=4644.006

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7655.37 - 2531.102 - ( 252.519 - max(0, 2736.581 - 3387.84+252.519))
=4871.749

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Ebos Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=422.986/( ( (1004.081 + max(220.166, 0)) + (1001.752 + max(506.273, 0)) )/ 2 )
=422.986/( ( 1224.247 + 1508.025 )/ 2 )
=422.986/1366.136
=30.96 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1363.283 + 1342.73 + 42.731) - (2436.823 + 5.796 + 85.959)
=220.166

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1684.596 + 1360.259 + 90.466) - (2531.102 + 25.193 + 72.753)
=506.273

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ebos Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=397.706/4899.464
=8.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ebos Group EBIT Related Terms

Ebos Group EBIT Historical Data

* Premium members only.

The historical data trend for Ebos Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ebos Group EBIT Chart

Ebos Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 283.34 318.96 438.94 471.13 390.93

Ebos Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 233.32 239.11 200.41 186.21 211.49

ASX:EBO vs MCK, COR, CAH: EBIT Comparison

For the Medical Distribution subindustry, Ebos Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ebos Group EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Ebos Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ebos Group's EV-to-EBIT falls into.


ASX:EBO
77GF Score
Ebos Group Ltd ASX:EBO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ebos Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$398 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of A$398 Mil mean?
Ebos Group (ASX:EBO) has a EBIT of A$398 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ebos Group.
Is Ebos Group's EBIT too high?
Ebos Group's current EBIT is A$398 Mil. Overall, Ebos Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's EBIT compare to MCK and COR?
Ebos Group's EBIT of A$398 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ebos Group. Ebos Group's current EBIT is A$398 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.49, compared to a current price of A$16.76 — trading 46.8% below its estimated fair value. The current EBIT is A$398 Mil. Ebos Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current EBIT is A$398 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ebos Group (ASX:EBO) Overvalued in 2026?

Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued. The current stock price of A$16.76 is trading 46.8% below its estimated GF Value™ of A$31.49. GuruFocus considers Ebos Group to be Significantly Undervalued.

Key valuation signals for ASX:EBO:

  • EBIT: A$398 Mil
  • GF Value™: A$31.49 vs. price of A$16.76 (46.8% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ebos Group Business Description

Address 737 Bourke Street, Level 7, Docklands, Melbourne, VIC, AUS, 3008
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
77GF Score

Get the complete analysis for ASX:EBO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$16.76
Price
A$31.49
GF Value